TP53 and posterior cortical atrophy: PCa clinical samples further validated that TP53 R273 mutant tumors can remain heterozygous (Fig. 2B, right), indicating that ~50% of tumors retain WT TP53 in the context of a potential gain of function (GOF) R273 allele.